Introduction
Targeting PD-1 and CTLA-4 immune checkpoints have shown remarkable antitumor effects. The blockade of PD-1, CTLA-4 or a combination of the two in the treatment of cancers leads to distinct genomic and functional signatures in vivo in T cells and monocytes. Among these three therapies, the only shared feature is the upregulation of IFN-g gene expression.
1 CTLs regulate tumor growth via cytostatic effect mediated by IFN-g rather than the cytotoxic killing of tumor cells. 2 IFN-g is the most important cytokine implicated in anti-tumor immunity. IFN-g deficient mice spontaneously develop lung epithelial malignancies and lymphoma. 3 IFN-g receptor and STAT1 deficient mice exhibit tumor growth after chemical carcinogen treatment, confirming the anticancer ability of IFN-g. 4 More recent findings suggest loss of IFN-g-associated genes in tumor cells serves as a mechanism of resistance to anti-CTLA-4 and PD-1 blockade therapies in melanoma. 5, 6 Despite the significant anti-tumor effect, increasing evidence indicates that IFN-g can support tumor growth. Insensitivity to IFN-g due to impairment of the IFN-g receptor or IFN-g-mediated signal disrupted by various mechanisms may contribute to tumor development and progress. 7 IFN-g can induce PD-L1 expression on tumor cells, a phenomenon called "adaptive resistance." 8 Previously, we showed that PD-1 signaling in human T cells targets multiple regulators of the cell cycle, such as p27 kip1 , CDK2 and Smad3, which lead to the induction of T cell tolerance and blockade of cell cycle progression. 9 In addition, IFN-g can induce upregulation of PD-L1 on hematopoietic tumor cells thereby reducing tumor cells susceptibility to NK-mediated cytotoxicity. 10 Thus, the IFN-g-dependent PD-L1 expression could serve as a potent immune escape mechanism for cancer cells. However, it remains unclear the overall clinical outcome for tumors that express both IFN-g and PD-L1.
IFN-g exerts its biological effects via binding to the IFN-g receptor, this receptor consists of two subunits, IFNGR1 and IFNGR2. The intracellular domains of IFNGR1 and IFNGR2 are pre-associated with the JAK1 and JAK2 kinases, respectively. IFN-g activates mainly STAT1 transcriptional activator. Phosphorylated STAT1 anchors on the promoter of IFNstimulated genes (ISGs) to initiate transcription. In addition to the most characterized JAK-STAT pathway, other IFN-gmediated pathways, including PI3K-AKT, MAPK and NFjB, have been indicated in recent studies. [11] [12] [13] [14] Although multiple signaling pathways engaged by IFN-g have been identified, their specific roles and possible coordination in the generation of IFN-g-mediated biological responses remain unclear. A comprehensive understanding of IFN-g signaling and its associated functions in cancer might provide the necessary strategies to maximize the antitumor effect of IFN-g. In our study, we evaluated the prognostic value of IFN-g in lung adenocarcinoma. We also identified the downstream signaling pathways induced by IFN-g and subsequently investigated how these pathways regulate the effects of IFN-g in lung adenocarcinoma. Our study demonstrated the existence of cross-talk between JAK2-STAT1 and PI3K-AKT signaling in response to IFN-g and unraveled its underlying molecular mechanism.
Materials and Methods

Patients and tissue samples
Lung adenocarcinoma specimens were obtained from 50 patients, who underwent pulmonary resection prior to radiation or chemotherapy between 2012 and 2015 in the Department of Thoracic Surgery, Tong Ji Hospital. Histological diagnosis of tumors was based on the WHO criteria. The TNM stage was determined according to the 2010 AJCC staging guidelines. The use of human tissue samples was approved by the Huazhong University of Science and Technology Ethics committee.
Cell lines
A549, H1975 and HCC827 cell lines were obtained from Cobioer Biosciences (Nanjing, China). Authentication of these cell lines was performed by short tandem repeat (STR) DNA profile at Cobioer Biosciences in 2017. All cell lines were passaged for fewer than 6 months after resuscitation. All cell lines were maintained in 10% fetal bovine serum (FBS)-containing RPMI 1640 medium supplemented with 1% penicillin/streptomycin. FBS was obtained from GIBCO (Grand Island, NY) and penicillin/streptomycin was from Hyclone (Logan, UT).
Immunohistochemistry staining
Consecutive sections of formalin-fixed, paraffin-embedded samples were used and dried overnight. Slides were dewaxed and rehydrated. Antigen retrieval was performed by microwave heating (400 W) for 15 min in EDTA retrieval buffer (pH 9, preheating buffer to 1008C). Endogenous peroxidase activity was blocked by incubation in 3% hydrogen peroxide for 10 min. After washing in PBS three times, the sections were treated with 5% bovine serum albumin for 30 min. Subsequently, the sections were incubated with the primary antibodies at 48C overnight. The primary antibodies and their working dilutions were shown in Supporting Information Table S1 . The PD-L1 staining intensity was scored as weak (1), moderate (2) and strong (3) . The percentage of PD-L1 positive tumor cells was scored as 1 (0-5%, low), 2 (5-50%, mediate) and 3 (50-100%, high). We then multiplied the two numbers to obtain the final score for the PD-L1 IHC staining. The score of PD-L1 IHC staining 4 was considered to be positive for PD-L1 expression. Two independent observers (L.L. and G.Y.) examined the stained slides in a blinded fashion.
The numbers of infiltrating T cells in tumor bed and tumor stromal were calculated separately at 3400 magnification by Image-Pro Plus 6.0 software in three areas containing the highest abundance of CD3 1 T cells. The number of CD3 1 T cells was determined by the average value of the three areas.
Quantitative real-time PCR analysis
The trizol method (Invitrogen, Carlsbad, CA) was used for RNA isolation. RNA was reverse transcribed into cDNA by using the RT reagent Kit (TAKARA, Dalian, China) according to the manufacturer's protocol. 18S was used as internal control. Relative expression of the target genes was determined using the D DCT method. Fast SYBR Green Master Mix was obtained from Applied Biosystems (Vilnius, Lithuania). The primers were obtained from OriGene Technologies (Rockville, MD) and the sequences for primers were shown in Supporting Information Table S2 .
Transfections
Reverse transfection was used to deliver siRNA (RiboBio, Guangzhou, China) into cells. 15 siRNA (25 nM) and
What's new?
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Lipo3000 (Invitrogen) were gently premixed in medium without serum according to the guideline. After adding the transfection mixture to the culture plate, cell suspension was seeded into the culture plate.
Cell proliferation assay
The effect of IFN-g (Life Technologies, Carlsbad, CA) and LY294002 (Cell Signaling Technologies, Danvers, MA) on cell proliferation was assessed by CCK-8 kit (Dojindo Molecular Laboratories, Kumamoto, Japan). Cell suspension was seeded (4,000-5,000/100 lL/well) and cultured overnight before exposure to IFN-g. The absorbance was measured at 450 nm using a microplate spectrophotometer (TECAN).
Flow cytometry
Cultured cells were harvested and stained with antibody against PD-L1 (Supporting Information Table S1 ) or isotype control obtained from BioLegend (San Diego, CA). The cells were run on a FACS LSR II, and analyzed using FLowJo software (TreeStar, Ashland, OR).
Western blot
Cell lysates were prepared as previously described. 9 Antibodies used were shown in Supporting Information Table S1 . Rapamycin was purchased from MedChem Express (Junction, NJ).
Microarray analysis
Gene expression profiles were assessed by Agilent SurePrint G3 Human GeneExpression 8 3 60 K V3 Array (Agilent Technologies, Santa Clara, CA). Total RNA was amplified and labeled by OneColor Low Input Quick Amp Labeling Kit (Agilent Technologies). 600 ng Cy3-labeled Complementary RNA (cRNA) was hybridized with each slide. After washing, slides were scanned through an Agilent G2565CA Microarray Scanner. Signals were extracted via Feature Extraction software 10.7 (Agilent Technologies) and normalized signal values were converted into base-2 logarithmic values. p <0.05 and fold change 2 was the criteria to select differentially expressed genes.
Gene ontology (GO) term and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of these differentially expressed genes were performed by the ShanghaiBio Corporation (SBC) analysis system, employing clusterProfiler data from R/bioconductor software (http:// www.r-project.org and http://www.bioconductor.org/) with public databases GO (http://www.geneontology.org) and KEGG (http://www.genome.jp/kegg). Fisher's exact test was used for calculating the enrichment p-values.
Accession number the dataset was deposited in GEO (accession number: GSE99995).
Statistical analysis
Statistical analyses were performed with GraphPad Prism6. Data in bar graphs are presented as means 6 SD. The correlations between IFN-g expression and other variables were determined by Pearson or Spearman correlation coefficients. The association of clinical characteristics and PD-L1 expression was analyzed using v 2 test or Student's t-test as appropriate. The disease-free survival (DFS) was estimated by the Kaplan-Meier method. Differences were considered to be statistically significant at a two-side p < 0.05.
Results
Co-expression of PD-L1 and IFN-c in the tumor microenvironment indicates a favorable prognosis in patients with locally advanced lung adenocarcinoma IFN-g is an effector cytokine produced during effective antitumor immune responses. 16 We evaluated the association of IFN-g expression and the immune status in tumors. Since T cells are the major producer of IFN-g, we examined the correlation between IFN-g expression and the density of tumor infiltrating CD3
1 T lymphocytes. Expression of IFN-g was correlated with the number of CD3 1 T lymphocytes within the tumor bed ( . 17 The analysis of 26 cases showed a significant association between the expression of IFN-g and GZMB ( IFN-g expression serving as an independent prognostic factor has been reported in ovarian cancer and invasive cervical carcinoma. 18, 19 We examined whether IFN-g expression has a prognostic value in lung adenocarcinoma. First, we analyzed the association of IFN-g expression and DFS in the lung adenocarcinoma using online survival analysis tool Kaplan-Meier plotter (http://kmplot.com/analysis/). KMplotter was established using published lung cancer microarray datasets to identify biomarkers related to survival. 20 To analyze the prognostic value of IFN-g, the cohort was divided into two groups according to the median expression (IFNg high group, n 5 231 and IFN-g low group, n 5 230). Expression levels of IFN-g were not associated with DFS ( Fig. 1d ; p 5 0.552). The database used included patients with lung adenocarcinoma at heterogeneous stages. Next, we examined the correlation between IFN-g expression and DFS in a uniform cohort of a total of 44 patients with locally advanced lung adenocarcinoma (IIIA) from our patient archive. The clinicopathological characteristics of the patients were presented in Supporting Information Table S3 . All patients were divided into two groups according to their tumor tissue IFNg expression levels. IFN-g expression below the median 2DCT value (215.65, CT 18S -CT IFNG ) was considered as IFN-g2 whereas expression levels above the median 2DCT value was considered IFN-g Approximately one-third of melanoma and lung adenocarcinoma cell lines have been shown to have inactivating mutations in the IFN-g pathway components, 21 which raises the possibility that tumor insensitivity to IFN-g may be a mechanism used by cancers to evade tumor surveillance. We examined whether the responsiveness of primary tumor cells to IFN-g could determine the clinical outcome of IFN-g in lung cancer. IFN-g induces PD-L1 expression in tumor cells. 22 To determine the relationship between IFN-g and PD-L1 expression on tumor cells, we analyzed PD-L1 expression by IHC staining of biopsy specimens. PD-L1 expression was quantified by multiplying the staining intensity scores by the percentage scores (Supporting Information Fig. S1a ). Eighteen out of 50 (36%) specimens were stained positive for PD-L1 (PD-L1 1 ), and PD-L1 expression was not associated with patient clinicopathological features and had no prognostic value in patients with locally advanced lung adenocarcinoma (Supporting 
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Information Table S4 and Fig. S1b ). The expression levels of IFN-g were not correlated with PD-L1 expression on tumor cells ( Fig. 1f ; n 5 44, p 5 0.691). In fact, 14 out of 23 tumor specimens with high IFN-g expression were not PD-L1 positive (Supporting Information Fig. S1c) .
To determine whether PD-L1 expressed on tumor cells in the presence of IFN-g was related to IFN-g-mediated signaling, we assessed the expression of IRF-1, which is a direct target of IFN-g-STAT1 signaling. 16 A recent study using cell lines shows a strong correlation between basal status of IRF-1 activation and its IFN-g-induced activation. Moreover, IRF-1 responsiveness to IFN-g indicates the different intrinsic properties of cancer cells. 23 Significantly increased expression of IRF-1 was observed in tumor tissues from the IFN-g 1
PD-L1
1 group compared to other groups ( Fig. 1g; Whole-transcriptome analysis of lung cancer tissues reveals molecular changes induced by IFN-c
Our above results provided evidence for the clinical significance of the combined IFN-g-mediated signaling and PD-L1 expression in lung adenocarcinoma. To obtain detailed understanding of the molecular implications of IFN-gmediated signaling in the tumor microenvironment, we performed global gene expression analysis using the Agilent oligonucleotide microarray system. Biopsy specimens from 12 lung adenocarcinoma patients were included. Six of the biopsy specimens contained high levels of IFN-g while others expressing IFN-g at low levels, termed IFN-g 1 group and IFN-g2 group, respectively. We identified a total of 285 transcripts differentially expressed in these two groups (fold changes 2, p < 0.05, Supporting Information Fig. S2a) . By GO-term analysis of differentially expressed genes, we found nine enriched GO terms were associated with biological processes that are related to immunity, including inflammatory response, immune cell migration and T-cell-mediated response (Supporting Information Fig. 2b and Table S5 ).
The IFN-g 1 group was divided into two subgroups according to PD-L1 expression, IFN-g 1 PD-L1 1 and IFN-g 1 PD-L12 groups. A total of 1,518 gene probes were differentially expressed in the specimens from IFN-g 1
1 group and IFN-g 1 PD-L12 group (fold changes 2, p < 0.05). The differentially expressed gene probes from patients were depicted in a heatmap (Supporting Information Fig. S2c) . To identify the possible signaling pathways that were affected under the influence of IFN-g, we performed KEGG pathway enrichment analysis. Significantly regulated pathways are shown in Supporting Information Figure S2d . The cell cycle pathway was a key target. The top 11 most significantly differentially expressed genes in the cell cycle pathway are shown in Table 1 and their regulatory functions in cell cycle progression are illustrated in Supporting Information Figure S2e . The expression of E2F1, E2F2, Cyclin E2 (encoded by CCNE2), Cyclin B1 (encoded by CCNB1), Cdc25A and Cdc25C was significantly reduced in the specimens expressing both IFN-g and PD-L1 compared to those expressing IFN-g only. Interestingly, the only significantly upregulated gene in IFN-g 1 PD-L1 1 group was growth arrest and DNA damage 224 alpha (GADD45A). Thus, our microarray analysis demonstrated the molecular mechanism of the significant anti-proliferative effect of IFN-g in tumor tissues that express PD-L1.
IFN-c induces activation of JAK2, STAT1, STAT3 and AKT in lung adenocarcinoma cell lines
Our studies showed that patients with locally advanced lung adenocarcinoma expressing both IFN-g and PD-L1 had an improved prognosis. In such cases, these results indicate that PD-L1 expression in tumor cells is induced in response to IFN-g, and the anti-proliferative effect of IFN-g might be the dominant force that determines the clinical outcome. However, it is well established that highly expressed PD-L1 on tumor cells suppresses anti-tumor immune responses. 7 Therefore, understanding how the signaling mechanisms downstream of IFN-g regulate PD-L1 expression is critically important. To address this question, we used three lung adenocarcinoma cell lines A549, HCC827 and H1975 harboring frequent mutations, such as mutations in KRAS (A549), 
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EGFR (H1975, HCC827), PIK3CA (H1975) and TP53 (H1975, HCC827), in an effort to reflect the mutational spectrum seen in patients. All three cell lines expressed IFNGR1 and IFNGR2 (Supporting Information Fig. S3a ). Addition of IFN-g at the low concentration of 10 U/mL induced PD-L1 expression in the A549 cell line (Supporting Information Fig.  S3b ). As shown in Figure 2a , flow cytometry analysis revealed that the baseline expression of PD-L1 on H1975 and HCC827 was higher compared to that expressed on A549.
Similarly to A549, the expression levels of PD-L1 in H1975 and HCC827 were further increased after exposure to IFN-g. Moreover, cell culture supplemented with IFN-g significantly decreased proliferation in all three cell lines (Figs. 2b and 2c) . Addition of IFN-g in the cell culture did not induce significant PARP cleavage, indicating that IFN-g at the given concentration had no significant effect on the induction of cell apoptosis (Supporting Information Fig. S3c ).
To investigate the signaling events mediated by IFN-g, we first examined the activation status of JAK2, which is the initial step of the signaling cascade, upon exposure to IFN-g. IFN-ginduced increased levels of JAK2 phosphorylation as early as 15 min (Figs. 2d and 2e) . As expected, IFN-g stimulation resulted in a robust and sustained activation of STAT1 as determined by phosphorylation of STAT1 at Y701 (Figs. 2d and 2e and Supporting Information Fig. S3d ). As shown in Figures 2d and 2e , a transient increase in the phosphorylation of STAT3 was also observed upon IFN-g stimulation at 15 min of IFN-g incubation, which declined by 60 min in H1975 and HCC827. Unexpectedly, IFN-g-induced phosphorylation of AKT at serine 473 (S473) in all three cell lines. This was apparent after 15, 30 and 60 min in A549, HCC827 and H1975, respectively, and lasted at least 6 hr in A549 and H1975 cell lines in the presence of IFN-g (Supporting Information Fig. S3d ). An increased phosphorylation of ERK1/2 was observed at 60 min of IFN-g stimulation in H1975 and HCC827 but not in A549. Phosphorylation of IjB was only detected increased in HCC827 in response to IFN-g during this time period (Figs. 2d and 2e) . IRF-1 expression was markedly upregulated in all three lung cancer cell lines treated with IFN-g (Fig. 2f) . Our results show that in lung adenocarcinoma, IFN-g induces strong and sustained JAK2-STAT1 activation. In addition, IFN-g actives alternative pathways as evidenced by increased phosphorylation of STAT3 and AKT.
JAK2-STAT1 is required for IFN-c-mediated antiproliferation and induction of PD-L1 expression
We utilized a loss-of-function approach to investigate the biological relevance of JAK2, STAT1 and STAT3 in IFN-gmediated effects in lung cancer. First, we examined whether IFN-g-induced activation of STAT1, STAT3 and AKT in cancer cells after exposure to IFN-g was dependent on JAK2. For this purpose, we used siRNA to induce knockdown of JAK2 and the efficacy of our approach in decreasing JAK2 expression was confirmed at mRNA and protein levels (Supporting Information Figs. S4a and S4b). JAK2 knockdown decreased the phosphorylation of STAT1, STAT3 as well as AKT in all tested cell lines upon exposure to IFN-g (Figs. 3a and 3b) . Induction of IRF-1 in response to IFN-g was markedly reduced in cells transfected with JAK2 siRNA compared to cells transfected with control siRNA (Fig. 3c) . Moreover, downregulation of JAK2 by siRNA in H1975 cells reversed IFN-g-mediated reduction of cell proliferation (Fig. 3d) and abrogated the IFN-ginduced PD-L1 mRNA expression (Fig. 3e) . Together, our data demonstrate that the activation of JAK2 is a trigger step in the IFN-g-mediated signal transduction and plays a critical role in mediating the biological function of IFN-g in lung cancer.
Next, we investigated the relative contribution of STAT1 on IFN-g-mediated biological effects. siRNA targeted STAT1 knockdown efficiently suppressed total STAT1 expression (Supporting Information Figs. S4c and S4d) . Knockdown of STAT1 significantly antagonized the anti-proliferation effect of IFN-g (Fig. 3f) and abrogated IFN-g-induced PD-L1 upregulation at mRNA and protein levels (Supporting Information Fig. S4e and Fig. 3g ). Lastly, we sought to determine the role of STAT3 in mediating the function of IFN-g in lung cancer cells. Knockdown of STAT3 by siRNA did not affect IFN-g-mediated anti-proliferation effect on A549 and H1975 cells (Supporting Information Figs. S4f and S4g and Fig. 3h ). As shown in Figure 3i , knockdown of STAT3 had no obvious effect on IFN-g-induced PD-L1 expression in lung cancer cells. Our data suggest that activation of JAK2-STAT1 is responsible for IFN-g-mediated anti-proliferative effect and for the induction of PD-L1 expression.
Inhibition of PI3K enhances the anti-proliferative effect of IFN-c and downregulates IFN-c-induced PD-L1 expression in lung adenocarcinoma
It is well known that activation of PI3K-AKT pathway promotes cellular proliferation and protein synthesis in cancer cells. 24 However, the cross talk between PI3K-AKT and IFN-gmediated pathways in lung cancer cells has not been elucidated. To determine the role of PI3K-AKT signaling on IFN-gmediated functions, tumor cells were treated with the pharmacologic inhibitor of PI3K, LY294002. As shown in Figure 4a , in HCC827 and H1975 cells but not in A549 cells treatment with 10 lM of LY294002 abrogated IFN-g-induced phosphorylation of AKT. LY294002 given at 50 lM significantly reduced IFN-ginduced phosphorylation of AKT in A549 cells, indicating that these cell lines displayed diverse sensitivity to PI3K inhibitor. Addition of LY294002 in cell cultures led to significant inhibition of proliferation in all three tested cell lines. Combining IFN-g with LY294002 exhibited a synergistic effect on suppressing proliferation (Fig. 4b) . Treatment with LY294002 also resulted in downregulation of IFN-g-induced PD-L1 expression at mRNA (Fig. 4c ) and protein levels (Figs. 4d-4f) .
Inhibition of PI3K attenuates IFN-c-mediated STAT1 phosphorylation and transcription of STAT1 targeted genes
In subsequent studies, we sought to determine the underlying mechanism by which PI3K inhibition affected IFN-g- mediated PD-L1 expression. A previous study showed that oncogenic activation of the AKT-mTORC1 pathway controls PD-L1 expression in lung cancer. 25 We examined whether IFN-g activates AKT/mTOR signaling in lung cancer cells. Ribosomal protein S6 and 4E-BP1 were significantly phosphorylated in response to IFN-g (Fig. 5a ), suggesting that IFN-g activates the AKT/mTORC1 pathway. To determine whether IFN-g-induced PD-L1 expression was dependent on activation of mTOR signaling, the H1975 cell line was treated with the mTOR pharmacologic inhibitor Rapamycin. Addition of Rapamycin in the cell culture inhibited IFN-ginduced activation of mTOR signaling (Fig. 5b) . The effect of Rapamycin on IFN-g-induced PD-L1 expression was not observed at 24 hr of the treatment (Figs. 5c-5d ). IFN-gmediated PD-L1 expression was reduced after 48 hr of treatment with Rapamycin but to a lesser extent compared to PI3K inhibitor (inhibition rate was 21.8% and 31.8%, respectively), suggesting that additional mechanisms are involved in PI3K-AKT-regulated PD-L1 expression. STAT1 is required for IFN-g-induced PD-L1 expression. We examined whether inhibition of PI3K activity might alter IFN-g-dependent STAT1 activation. To obtain full transcriptional activity, STAT1 must be phosphorylated on both Y701 and S727 sites. 26 As shown in Figures 5e and 5f, phosphorylation of STAT1 on Y701 and S727 upon IFN-g incubation was detected in all three cell lines. IFN-g-mediated phosphorylation of STAT1 on S727 was significantly reduced by the addition of LY294002. IFN-g-induced phosphorylation of STAT1 on Y701 was also slightly downregulated by LY294002 in H1975 and HCC827 cell lines but not in the A549 cell line. To further establish the functional role of PI3K-AKT signaling in regulating STAT1 phosphorylation, we examined transcription of interferon-stimulated genes (ISGs) in the presence of LY294002. CXCL10 and CXCL9 are IFN-ginduced genes, which play a critical role in recruiting lymphocytes into tumors. [27] [28] [29] Expression of CXCL10 and CXCL9 mRNA was markedly induced by IFN-g (Supporting Information Figs. S5a and S5b). Addition of PI3K inhibitor significantly reduced IFN-g-mediated upregulation of CXCL10 and CXCL9 expression (Fig. 5g) . As illustrated in Figure 5h , exposure of lung cancer cells to IFN-g activated the PI3K-AKT pathway and in turn, the PI3K-AKT pathway regulated the transactivation activity of STAT1 thereby affecting IFN-g-mediated biological functions.
Discussion
Given the known importance of IFN-g in anti-tumor immunity, several research studies and clinical trials have considered IFN-g as a therapeutic target. The various modalities of IFN-g treatment have not provided significant survival advantage over conventional cancer therapy. 30 Tumor cells unresponsive to IFN-g account for one of the mechanisms underlying the failure of IFN-g treatment in cancer. How one can recognize whether primary tumor cells respond to IFN-g in vivo and whether patients with tumors that respond to IFN-g could have a better clinical outcome? IFN-g induces PD-L1 expression in almost all cell types including cancer cells. In our study, however, we found 14 out of 23 tumor samples with high IFN-g expression were not PD-L1 positive as determined by immunohistochemistry staining. Agilent microarray analysis revealed that the expression of cell cycle pathway-related genes in IFN-
1 tumor tissues were different from those expressing IFN-g alone. The regulatory molecules of cell cycle including E2F1, E2F2, Cyclin B1, Cyclin E, which play essential roles in promoting cell proliferation, were markedly downregulated in IFN-g 1 PD-L1 1 tumor tissues compared to the ones expressing IFN-g alone. E2F1 and E2F2 are considered as positive regulators of cell cycle progression and play a major role during the G1/S transition. 31 Cyclin E2 is another important factor, which is required for the transition from G1 to S phase of the cell cycle. 32 Cyclin B1 is expressed minimally in G1, begins to rise in S phase, and peaks at the G2/M transition and is required for the activation of mitosis. 33 Cdc25 is a dual-specific phosphatase. In mammalian cells, three isoforms: Cdc25A, Cdc25B and Cdc25C have been implicated in the control of cell cycle transitions from G1 to S phase and G2 to M phase by regulating the activities of CDK1 and CDK2. 34 In contrast, the expression of GADD45 was upregulated in IFN-g 1
PD-L1
1 tumor tissues. When GADD45A is deleted or repressed, cells show uncontrolled proliferation. In addition, decreased GADD45A expression is considered a survival mechanism of cancer cells. 35 Although PD-L1 expression on tumor cells suppresses antitumor immune responses, PD-L1 expression on tumor cells could be an indicator of tumor cells capable of responding to IFN-g. In this case, the anti-tumor effect of IFN-g might outperform the tumor-promoting effect of PD-L1. Indeed, we found that patients with locally advanced lung adenocarcinoma tumors co-expressing high levels of IFN-g and PD-L1 have significantly improved prognosis compared to those with tumors lacking IFN-g or having IFN-g but no PD-L1 expression.
Recent studies have showed that the status of tumor expression of PD-L1 and tumor infiltrating T lymphocytes serve as predictive biomarkers for identifying patients most likely to benefit from PD-1/PD-L1-based immunotherapy. 36, 37 Our clinical data showed that IFN-g is significantly correlated with the status of tumor infiltrating T lymphocytes. IFN-g also regulates the expression of PD-L1 on tumor. For these reasons, we speculate that patients with tumors expressing both IFN-g and PD-L1 may act as better predictive markers for PD-1/PD-L1 blockade immunotherapy.
One of the significant findings of our study is the observation that IFN-g triggered the activation of PI3K-AKT pathway in all three IFN-g-sensitive lung adenocarcinoma cell lines in a JAK2 dependent manner. Our study examined the functional relevance of this pathway in IFN-g-mediated function. We found that inhibition of PI3K activity enhanced the anti-proliferative effect of IFN-g, indicating the activation of PI3K-AKT pathway by IFN-g might antagonize the antiproliferative effect of IFN-g. PI3K-AKT activation driven by oncogene mutations regulates PD-L1 expression at the mRNA translation level and in an mTORC1-dependent manner. 25 Studies have shown that IFN-g-induced PD-L1 expression in human melanoma cells was not affected by activation of the PI3K-AKT pathway. 13 We found that inhibition of PI3K led to a significant reduction of PD-L1 mRNA and protein level expression in lung adenocarcinoma cell lines. It is worth noting that lung cancer cell lines displayed a differential sensitivity to the PI3K inhibitor LY294002. The A549 cell line was less sensitive to LY294002 compared to H1975. One possible explanation might be that A549 is a lung adenocarcinoma cell line with a mesenchymal signature. The NSCLC cell lines with mesenchymal signatures are more resistant to drugs targeting the PI3K-AKT pathway. 38 In addition, we also found that IFN-g-induced increased phosphorylation of STAT3. Activation of STAT3 as a downstream target of EGFR signaling regulated PD-L1 expression. 39 However, STAT3 as a downstream target of IFN-g does not affect IFNg-induced PD-L1 expression in head and neck cancer. 40 Similarly, our data suggest that STAT3 has no obvious effect on IFN-g-induced PD-L1 expression and proliferation in lung adenocarcinoma. The biological consequences of STAT3 activation in lung adenocarcinoma in response to IFN-g requires further investigation.
STAT1 is the central mediator of IFN-g-induced gene expression and its transactivation activity is tightly regulated by its phosphorylation at Y701 and S727. Phosphorylation of STAT1 at Y701 by JAK2 is an essential prerequisite for dimerization and nuclear translocation. In addition, a serine/ threonine kinase phosphorylates the STAT1 at S727 and increases transcriptional competence. The interaction between STAT1 transcription activation domain (TAD) and DNA helicase MCM5 has been shown to depend on the phosphorylated S727 in the STAT1 TAD.
41 PI3K-AKT is involved in the IFN-g-induced phosphorylation of STAT1 S727. 42 Our mechanistic analysis revealed that inhibition of AKT activation resulted in the downregulation of IFN-g-mediated phosphorylation of STAT1 at S727 sites in A549, HCC827 and H1975 cell lines. The precise mechanisms of how PI3K-AKT and its downstream effectors regulate the phosphorylation of S727 in STAT1 are currently under investigation. Besides regulating PD-L1 expression, PI3K inhibitor downregulated the expression of STAT1 target genes CXCL10 and CXCL9. Our data indicate that PI3K-AKT affects expression of IFN-gstimulated genes via regulating the phosphorylation of STAT1 thereby modulating its transactivation activity. We speculate that inhibition of the PI3K-AKT pathway reduces not only cell proliferation and PD-L1 expression but also alters the cellular responsiveness to IFN-g. One of the great challenges to fully elucidating the complex role of IFN-g in cancer is that the IFN-g-induced signaling is always integrated with signaling mediated by other factors. Unraveling the involvement of STAT1 in the crosstalk between JAK-STAT1 and PI3K-AKT pathways will enable a more realistic view of the in vivo function of IFN-g during the development of human lung adenocarcinoma and the role of IFN-g in resistance to immunotherapy. For the first time, we have demonstrated in lung adenocarcinoma cells that IFN-g induced the activation of PI3K-AKT pathway, and in turn, PI3K-AKT was involved in regulating IFNg-mediated STAT1 activity. Our study provides a rationale for the combined treatment of PI3K inhibition with immunotherapies for lung adenocarcinoma.
